JP2019511485A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511485A5 JP2019511485A5 JP2018546039A JP2018546039A JP2019511485A5 JP 2019511485 A5 JP2019511485 A5 JP 2019511485A5 JP 2018546039 A JP2018546039 A JP 2018546039A JP 2018546039 A JP2018546039 A JP 2018546039A JP 2019511485 A5 JP2019511485 A5 JP 2019511485A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- nhr
- imidazol
- benzo
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 37
- 125000001475 halogen functional group Chemical group 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 8
- -1 -C l -C 6 alkyl Chemical group 0.000 claims description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 5
- 229960003957 dexamethasone Drugs 0.000 claims description 5
- PXXPZRNJBWKSPX-UHFFFAOYSA-N 4-[[1-(cyclohexylmethyl)benzimidazol-2-yl]amino]-N-hydroxybenzamide Chemical compound C1(CCCCC1)CN1C(=NC2=C1C=CC=C2)NC1=CC=C(C(=O)NO)C=C1 PXXPZRNJBWKSPX-UHFFFAOYSA-N 0.000 claims description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 4
- 208000034951 Genetic Translocation Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- GWZBNICNEZHVTD-UHFFFAOYSA-N FC1=CC2=C(N(C(=N2)NC2=CC=C(C(=O)NO)C=C2)CC2CCOCC2)C=C1 Chemical compound FC1=CC2=C(N(C(=N2)NC2=CC=C(C(=O)NO)C=C2)CC2CCOCC2)C=C1 GWZBNICNEZHVTD-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- ZXRAVTDQIHCBPZ-UHFFFAOYSA-N 4-[(1-cycloheptylbenzimidazol-2-yl)amino]-N-hydroxybenzamide Chemical compound C1(CCCCCC1)N1C(=NC2=C1C=CC=C2)NC1=CC=C(C(=O)NO)C=C1 ZXRAVTDQIHCBPZ-UHFFFAOYSA-N 0.000 claims description 2
- GLWKVGFPAGPIKY-UHFFFAOYSA-N 4-[(1-cyclohexylbenzimidazol-2-yl)amino]-N-hydroxybenzamide Chemical compound C1(CCCCC1)N1C(=NC2=C1C=CC=C2)NC1=CC=C(C(=O)NO)C=C1 GLWKVGFPAGPIKY-UHFFFAOYSA-N 0.000 claims description 2
- FIXWIPRWEQGXSK-UHFFFAOYSA-N 4-[[1-(cyclopentylmethyl)benzimidazol-2-yl]amino]-N-hydroxybenzamide Chemical compound C1(CCCC1)CN1C(=NC2=C1C=CC=C2)NC1=CC=C(C(=O)NO)C=C1 FIXWIPRWEQGXSK-UHFFFAOYSA-N 0.000 claims description 2
- WVYXIHXHHFJZAV-UHFFFAOYSA-N 4-[[1-[(4,4-difluorocyclohexyl)methyl]benzimidazol-2-yl]amino]-N-hydroxybenzamide Chemical compound FC1(CCC(CC1)CN1C(=NC2=C1C=CC=C2)NC1=CC=C(C(=O)NO)C=C1)F WVYXIHXHHFJZAV-UHFFFAOYSA-N 0.000 claims description 2
- SPYJQWGNNZBTIL-UHFFFAOYSA-N C1(CCCC1)CCN1C(=NC2=C1C=CC=C2)NC1=CC=C(C(=O)NO)C=C1 Chemical compound C1(CCCC1)CCN1C(=NC2=C1C=CC=C2)NC1=CC=C(C(=O)NO)C=C1 SPYJQWGNNZBTIL-UHFFFAOYSA-N 0.000 claims description 2
- 206010058314 Dysplasia Diseases 0.000 claims description 2
- XQFKWGSGTIPYIC-UHFFFAOYSA-N FC1(CCC(CC1)CN1C(=NC2=C1C=CC(=C2)F)NC1=CC=C(C(=O)NO)C=C1)F Chemical compound FC1(CCC(CC1)CN1C(=NC2=C1C=CC(=C2)F)NC1=CC=C(C(=O)NO)C=C1)F XQFKWGSGTIPYIC-UHFFFAOYSA-N 0.000 claims description 2
- HUXHETCMKDGIFU-UHFFFAOYSA-N FC1(CCCCC1)CN1C(=NC2=C1C=CC=C2)NC1=CC=C(C(=O)NO)C=C1 Chemical compound FC1(CCCCC1)CN1C(=NC2=C1C=CC=C2)NC1=CC=C(C(=O)NO)C=C1 HUXHETCMKDGIFU-UHFFFAOYSA-N 0.000 claims description 2
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims description 2
- 206010054949 Metaplasia Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 230000015689 metaplastic ossification Effects 0.000 claims description 2
- 210000004214 philadelphia chromosome Anatomy 0.000 claims description 2
- 208000015768 polyposis Diseases 0.000 claims description 2
- 231100000357 carcinogen Toxicity 0.000 claims 1
- 239000003183 carcinogenic agent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 239000013543 active substance Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 2
- 229960000688 pomalidomide Drugs 0.000 description 2
- 150000008071 10-membered heterocyclic compounds Chemical class 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 208000000321 Gardner Syndrome Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302781P | 2016-03-02 | 2016-03-02 | |
| US62/302,781 | 2016-03-02 | ||
| PCT/US2016/033841 WO2017151165A1 (en) | 2016-03-02 | 2016-05-23 | Aminobenzimidazole derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511485A JP2019511485A (ja) | 2019-04-25 |
| JP2019511485A5 true JP2019511485A5 (https=) | 2019-06-27 |
| JP6768078B2 JP6768078B2 (ja) | 2020-10-14 |
Family
ID=59744272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546039A Active JP6768078B2 (ja) | 2016-03-02 | 2016-05-23 | アミノベンゾイミダゾール誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190040017A1 (https=) |
| EP (1) | EP3423439A4 (https=) |
| JP (1) | JP6768078B2 (https=) |
| CN (1) | CN109071460B (https=) |
| AU (1) | AU2016394945A1 (https=) |
| CA (1) | CA3053238A1 (https=) |
| IL (1) | IL261201B (https=) |
| WO (1) | WO2017151165A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA031655B1 (ru) | 2014-02-11 | 2019-02-28 | Байер Фарма Акциенгезельшафт | Бензимидазол-2-амины в качестве ингибиторов midhi |
| US9951027B2 (en) | 2014-02-11 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
| WO2019051125A1 (en) * | 2017-09-06 | 2019-03-14 | Translational Drug Development, Llc | AMINOBENZIMIDAZOLE DERIVATIVES, TREATMENTS AND METHODS FOR INHIBITING HISTONE DEACETYLASE |
| US10780080B2 (en) * | 2016-11-23 | 2020-09-22 | Translational Drug Development, Llc | Benzamide and active compound compositions and methods of use |
| EP4373811A4 (en) * | 2021-07-21 | 2025-05-21 | Carna Biosciences, Inc. | NEW 1,2-DIAMINOBENZIMIDAZOLE DERIVATIVE |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007103755A2 (en) * | 2006-03-02 | 2007-09-13 | Smithkline Beecham Corporation | Thiazolones for use as pi3 kinase inhibitors |
| AU2010263113B2 (en) * | 2009-06-23 | 2015-11-26 | Translational Drug Development, Llc | Benzamide derivatives |
| EP2715956B1 (en) * | 2011-05-27 | 2019-09-11 | Cisco Technology, Inc. | Precision timing in a data over cable service interface specification (docsis) system |
| EP2914112A4 (en) * | 2012-11-05 | 2016-06-15 | Celgene Corp | TREATMENT OF CANCER WITH POMALIDOMIDE ON A PERSON WITH AFFECTED KIDNEY FUNCTION |
| EP3718569B1 (en) * | 2015-05-22 | 2023-05-03 | Translational Drug Development, LLC | Benzamide and active compound compositions and methods of use |
| JP6824954B2 (ja) * | 2015-07-16 | 2021-02-03 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | ｍＩＤＨ１阻害剤としての５−ヒドロキシアルキルベンズイミダゾール |
-
2016
- 2016-05-23 JP JP2018546039A patent/JP6768078B2/ja active Active
- 2016-05-23 WO PCT/US2016/033841 patent/WO2017151165A1/en not_active Ceased
- 2016-05-23 AU AU2016394945A patent/AU2016394945A1/en not_active Abandoned
- 2016-05-23 CA CA3053238A patent/CA3053238A1/en active Pending
- 2016-05-23 EP EP16892907.3A patent/EP3423439A4/en not_active Withdrawn
- 2016-05-23 US US16/074,706 patent/US20190040017A1/en not_active Abandoned
- 2016-05-23 CN CN201680085289.9A patent/CN109071460B/zh active Active
-
2018
- 2018-08-16 IL IL261201A patent/IL261201B/en unknown